Dosing Patterns for Octreotide LAR in Neuroendocrine Tumor (NET) Patients: NCCN NET Outcomes Database

Jonathan R. Strosberg, MD; Sarah Bobiak, PhD; Carrie C. Zornosa, MSPH; Michael A. Choti, MD; Emily K. Bergsland, MD; Al B. Benson, III, MD; P. Mark Bloomston, MD; Matthew H. Kulke, MD; Manisha H. Shah, MD; and James C. Yao, MD

1Moffitt Cancer Center, Tampa, FL 33612
2National Comprehensive Cancer Network, Fort Washington, PA 19034
3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University Baltimore, MD 21287
4UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143
5Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611
6The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, OH 43210
7Dana Farber Cancer Institute, Boston, MA 02215
8University of Texas MD Anderson Cancer Center, Houston, TX 77030

Background: Among patients (pts) with neuroendocrine histology, doses of 10 mg – 30 mg of octreotide-LAR administered intramuscularly every 4 weeks are FDA-approved for the long term treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and pancreatic VIPomas. In clinical practice, higher doses and/or more frequent administration are often prescribed for pts who experience refractory symptoms on the maximal labeled dose.

Methods: National Comprehensive Cancer Network (NCCN) created a comprehensive longitudinal database to characterize pts treated for NETs. This database was queried to identify pts presenting to 7 NCCN institutions, from 2004 to 2010, with a confirmed carcinoid or pancreatic NET (pNET) diagnosis who received octreotide LAR. The primary aim of this analysis was to describe octreotide LAR dosing patterns when beyond label recommendations.

Results: Among 1886 pts in the database, 271 carcinoid and pNET pts received octreotide LAR. 40% of carcinoid pts (n=82) and 23% of pNET pts (n=15) received octreotide LAR above-label dosing, defined by dose and/or frequency greater than 30 mg every 4 weeks. Reasons for above label dosing among carcinoid pts included uncontrolled symptoms (n=53, 65%), tumor progression (n=21, 25%), high urine 5-HIAA (n=1, 1%) and unknown (n=7, 9%). The most common dose/frequency combinations for carcinoid pts were 40 mg every 4 weeks (32 pts, 39%) and 40 mg every 3 weeks (15 pts, 18%). Among pNET pts, reasons for change included uncontrolled symptoms (n=5, 33%), tumor progression (n=9, 60%), and unknown (n=1, 7%).

Conclusions: Above label dosing of octreotide LAR is common in NCCN institutions. The primary indication is refractory carcinoid syndrome. Prospective studies are planned to validate this strategy.